|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
7 November 2016 |
|
Main ID: |
NCT02211612 |
|
Date of registration:
|
06/08/2014 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation
LIPOGAIN-2 |
|
Scientific title:
|
Role of Fatty Acids in Skeletal Muscle Hypertrophy and Ectopic Fat Accumulation During Overfeeding (LIPOGAIN-2) |
|
Date of first enrolment:
|
September 2014 |
|
Target sample size:
|
60 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02211612 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Sweden
| | | | | | | |
|
Contacts
|
|
Name:
|
Ulf Riserus |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Uppsala University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Body mass index 25-32
Exclusion Criteria:
- Type 2 diabetes
- Type 1 diabetes
- Kidney disease
- Liver disease
- Abnormal clinical chemistry at screening
- Intense physical exercise > 2 hours per week
- Use of statins or drugs affecting energy metabolism
- Use of extreme diets
Age minimum:
30 Years
Age maximum:
50 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Overfeeding
|
|
Obesity
|
|
Muscle Mass
|
|
Body Composition
|
|
Ectopic Fat
|
|
Intervention(s)
|
|
Dietary Supplement: SFA-group
|
|
Dietary Supplement: PUFA-group
|
|
Primary Outcome(s)
|
|
Change in lean tissue mass
[Time Frame: 10 weeks]
|
|
Secondary Outcome(s)
|
|
Change in circulating inflammation and coagulation markers
[Time Frame: 10 weeks]
|
|
Change in plasma lipids
[Time Frame: 10 weeks]
|
|
Change in hepatic fat content
[Time Frame: 10 weeks]
|
|
Change in pancreatic fat
[Time Frame: 10 weeks]
|
|
Change in insulin sensitivity
[Time Frame: 10 weeks]
|
|
Change in total adipose tissue
[Time Frame: 10 weeks]
|
|
Change in visceral adipose tissue (VAT)
[Time Frame: 10 weeks]
|
|
Secondary ID(s)
|
|
LIPOGAIN-2
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|